| Patent application number | Description | Published |
|---|
| 20080200445 | Heterocyclic aspartyl protease inhibitors -
Disclosed are compounds of the formula I
| 08-21-2008 |
| 20090258868 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 10-15-2009 |
| 20090306047 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 12-10-2009 |
| 20090312341 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT - Disclosed are novel compounds of the formula | 12-17-2009 |
| 20100063121 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors - Disclosed are compounds of the formula I | 03-11-2010 |
| 20100178294 | MACROCYCLIC BETA-SECRETASE INHIBITORS - Disclosed are novel compounds of the formula | 07-15-2010 |
| 20100247514 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. | 09-30-2010 |
| 20110237575 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) - The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I) | 09-29-2011 |
